Guide

Windsor Framework medicines: the UK-wide MA stack for Northern Ireland

The Windsor Framework (effective January 2025 for medicines) resolved the Northern Ireland Protocol's most disruptive consequence for the UK pharmaceutical supply chain — the requirement for EU-route marketing authorisation for medicines marketed in Northern Ireland. Under the Framework, MHRA is the sole regulator for all human medicines marketed anywhere in the United Kingdom (Great Britain + Northern Ireland), with a single UK-wide marketing authorisation, single UK-wide labelling/packaging requirements, and 'UK Only' physical labelling on packaging to prevent NI-licensed medicines crossing into the EU single market. Centralised procedure marketing authorisations issued by the EMA no longer apply in NI. Falsified Medicines Directive safety features (2D barcode, anti-tampering device) cease to apply to medicines marketed only in the UK under the Framework. The reform unwinds the dual-MA burden that built up 2021-2024 and aligns with the broader MHRA reform agenda including the International Recognition Procedure (IRP) launched January 2024 and the post-2024 Innovative Licensing and Access Pathway (ILAP).

Start free trial Free trial, no credit card, onboard in days, not months.

The Windsor Framework medicines stack — UK MA, UK Only packaging, NI supply

Layer 0 is the Windsor Framework political agreement (February 2023) and the implementing UK Statutory Instrument and EU Council Regulation that bring medicines into the Framework from January 2025. Layer 1 is the single UK-wide marketing authorisation — MHRA grants a UK MA covering GB + NI; existing GB-only MAs converted to UK-wide MAs and existing NI EMA centralised MAs (those that opted into the temporary EU-route framework) wound down. Layer 2 is single UK-wide labelling and packaging — single pack design for the entire UK with mandatory 'UK Only' marking to prevent diversion to EU markets. Layer 3 is supply-chain unwinding — wholesalers/distributors no longer need parallel GB and NI stockholding for centrally-authorised products; Falsified Medicines Directive (FMD) safety features (2D barcode, anti-tampering device) no longer apply to UK-only-marketed medicines (FMD still applies to medicines also marketed in EU/EEA). Layer 4 is GMP/GDP unchanged — MHRA inspectorate covers UK-wide; manufacturers maintain MIA/MIA(IMP) and WDA(H) licences as before.

Single UK marketing authorisation — converting from the dual regime

Pre-Windsor (2021-2024): centrally-authorised products operated under EU MA for NI and GB-only MA for GB (the Northern Ireland MHRA Authorisation Route, NIMAR, was the temporary bridge for unmet medical need). Post-Windsor: MHRA issues a single UK MA covering both jurisdictions. Conversion path — for products with both GB MA and EU centralised MA, MHRA processed conversion to UK-wide MA over 2024-2025 with grandfathering. For new products, the single UK MA route via national procedure or via International Recognition Procedure (IRP, drawing on FDA, EMA, Health Canada, TGA, Swissmedic, Singapore HSA, Japan PMDA approvals) is the default. MHRA also operates Project Orbis (oncology, with FDA and partner regulators) and the Innovative Licensing and Access Pathway (ILAP) for promising medicines. EU centralised procedure remains the route for EU + EEA market access — UK is no longer in scope.

UK Only labelling — the diversion prevention mechanism

Medicines authorised solely under the UK MA route (not also authorised in EU/EEA via centralised, mutual recognition or decentralised procedures) must carry 'UK Only' marking on the outer packaging. The marking signals that the product is not authorised for the EU single market and prevents diversion through Northern Ireland (the historical fear underpinning the Northern Ireland Protocol's medicines provisions). For products dual-authorised in UK and EU, the UK pack and the EU pack are separately compliant — UK pack does not need 'UK Only' if the same product is EU-authorised, but in practice many manufacturers maintain UK-specific packaging to leverage the FMD relief. MHRA guidance specifies font size, placement and language requirements for the 'UK Only' marking.

FMD relief and the safety-features regime

EU Falsified Medicines Directive safety features (2D DataMatrix with product code, serial number, batch, expiration, NHRN; anti-tampering device) no longer apply to medicines marketed only in the UK from January 2025. For medicines dual-marketed in UK and EU, the pack continues to carry FMD safety features. UK manufacturers and Marketing Authorisation Holders for UK-only products can save the cost of serialisation, decommissioning and SecurMed UK national repository scanning. SecurMed UK ceased operation for UK-only products at the Framework go-live; product decommissioning processes for dispensers in UK pharmacies stopped for UK-only products. The relief is conditional on the 'UK Only' label marking — products without 'UK Only' marking are presumed dual-marketed and must carry FMD features. UK manufacturers may continue voluntary serialisation for supply-chain visibility and anti-counterfeiting independent of FMD requirement.

Wholesale distribution, parallel import and NI supply

MHRA WDA(H) wholesale-distributor authorisation covers UK-wide as before. NI wholesalers no longer need separate EU wholesale authorisation for centrally-authorised products. Parallel import — UK MAs allow parallel-import licences via MHRA; EU-route parallel-import licences for NI ceased with the Framework. Supply-chain shortages and Serious Shortage Protocol (SSP) operate UK-wide. Generic substitution and pharmacy practice remain devolved (Scotland, Wales, NI have distinct pharmacy frameworks within UK MA scope). Hospital and specialist supply through homecare/specialist dispensary channels operates per the existing MHRA frameworks with NI access on equal footing.

Practical readiness — building for the Windsor Framework

Maintain the single UK MA file for each product with conversion-from-centralised audit trail where applicable. Convert pack artwork to single UK-wide design with 'UK Only' marking where the product is not also EU-authorised. Evaluate FMD serialisation for cost relief — if the product is UK-only, FMD serialisation is no longer required and decommissioning at point of dispense ceases. For dual UK/EU products, maintain dual packs and FMD features for the EU-marketed packs. Update wholesale-distribution and parallel-import processes to UK-wide scope. For NI supply, retire parallel inventory hubs and consolidate stockholding. For new MA applications, evaluate International Recognition Procedure (IRP) versus full national procedure based on reference-country approval status. Track MHRA International Recognition Procedure pathway maturity and the post-Brexit reform of the UK pharmaceutical regulatory framework.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Quality Management

Document control

Traceability

Industries this hits hardest

Pharmaceutical Veterinary pharma Radiopharmaceuticals

Frequently asked

Does the Windsor Framework apply to veterinary medicines?

Veterinary medicines have a separate Windsor Framework arrangement. The Veterinary Medicines Regulations 2013 (UK-wide) remain operative with implementation arrangements through 2025-2026 to address the post-Brexit veterinary supply to NI. The reform principles align with human medicines but the timeline and statutory framework differ — track Defra and VMD guidance.

Can I drop FMD serialisation immediately?

For UK-only-marketed products with 'UK Only' label marking, yes — FMD safety features no longer apply from the Windsor Framework go-live January 2025. For products dual-marketed in UK and EU/EEA, the FMD features continue to apply to the packs that may enter the EU single market. Many manufacturers retain voluntary serialisation for supply-chain visibility independent of FMD.

What about EU centralised MAs already in force for NI?

EU centralised MAs no longer apply to NI from January 2025 under the Windsor Framework. Existing centrally-authorised products marketed in NI were converted to UK-wide MA via MHRA grandfathering provisions. The Northern Ireland MHRA Authorisation Route (NIMAR) ceased as the bridge mechanism is no longer needed.

Do I still need a UK Responsible Person?

MA Holder discipline applies UK-wide. The Marketing Authorisation Holder for the UK MA must be UK-based or have appropriate UK presence per MHRA requirements. The QPPV (Qualified Person for Pharmacovigilance) for the UK is required and may or may not be the same as the EU QPPV depending on company structure. UK QP for batch release on UK-marketed product remains required per MIA(IMP) and MIA conditions.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →